Study type | Study group | Intervention | Findings | Reference |
---|---|---|---|---|
Pre-clinical | 24 rats (8/group) | Centrally administered ascorbate (0, 200, 600 nmol) | ↑ vasopressin release | [62] |
 |  |  | ↑ antidiuresis |  |
 |  |  | ↑ natriuresis |  |
Case report | Hospital patient | Intravenous ascorbate (1,500 mg/day) | ↑ arterial pressure | [35] |
 |  |  | ↓ heart rate |  |
 |  |  | Normalised central venous pressure |  |
 |  |  | ↓ need for catecholamines |  |
 |  |  | Improved multiple organ dysfunction |  |
Case report | Hospital patient | Oral ascorbate (500Â mg/day) | Resolution of orthostatic hypotension | [36] |
Clinical (retrospective) | 33 severely burned patients (16–17/group) | Intravenous ascorbate (0, 66 mg/kg/h) | ↓ fluid requirement | [39] |
 |  |  | ↓ number of patients requiring vasopressors |  |
Clinical (randomised, prospective) | 37 severely burned patients (17–18/group) | Intravenous ascorbate (0, 66 mg/kg/h) | ↓ resuscitation fluid volume | [38] |
 |  |  | ↑ diuresis |  |
 |  |  | ↓ length of mechanical ventilation |  |
Clinical (phase I randomised controlled trial) | 24 severe sepsis patients (8/group) | Intravenous ascorbate (0, 50, 200 mg/kg/24 h) | ↓ systemic organ failure | [12] |
 |  |  | ↑ systolic blood pressurea |  |
 |  |  | ↑ mean arterial pressurea |  |